In mid-June, the pharmaceutical company Farmak successfully passed a GMP inspection conducted by the Chinese regulatory authority — the NMPA (National Medical Products Administration). The inspection lasted five days and covered the company’s manufacturing facilities in Kyiv.
The National Medical Products Administration is China’s national regulatory agency responsible for oversight and control of pharmaceuticals, medical devices, and cosmetic products.
To export medical products to the Chinese market, a foreign manufacturing company must undergo an inspection and obtain approval from the NMPA, confirming compliance with Good Manufacturing Practice (GMP) standards.
During the inspection, representatives of the Chinese regulator thoroughly assessed Farmak’s quality management system and technical infrastructure, with a particular focus on manufacturing processes and quality control procedures.
The inspection confirmed a high level of transparency, compliance with international regulations, and the professionalism of the Farmak team.
Notably, Farmak became the first and so far the only pharmaceutical manufacturer in Ukraine to pass this type of inspection by the NMPA.
As a reminder, at the end of 2024, Farmak received its first marketing authorization in China for a diagnostic contrast agent used during magnetic resonance imaging (MRI).
Farmak Group is a global pharmaceutical business founded in Ukraine in 1925. It operates production facilities in two European countries (Ukraine and Spain) and has 11 companies and international offices in Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, and Moldova. Farmak Group’s products are exported to over 60 countries worldwide, including 15 EU countries, and are manufactured in accordance with high European GMP standards.
